Published in Invest New Drugs on February 01, 2003
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 2.52
Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One (2014) 1.26
The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal (2009) 1.25
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst (2015) 0.97
Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol (2012) 0.94
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
Combating immunosuppression in glioma. Future Oncol (2008) 0.87
The scavenger receptor MARCO modulates TLR-induced responses in dendritic cells. PLoS One (2014) 0.86
Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol (2012) 0.86
TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development. J Immunol Res (2014) 0.85
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
TGFβ in T cell biology and tumor immunity: Angel or devil? Cytokine Growth Factor Rev (2014) 0.85
Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment. Am J Transl Res (2012) 0.83
Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications. Int J Clin Exp Pathol (2014) 0.81
Distinct Functions of Neutrophil in Cancer and Its Regulation. Mediators Inflamm (2015) 0.80
The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer. MedGenMed (2007) 0.79
Effect of opiates, anesthetic techniques, and other perioperative factors on surgical cancer patients. Ochsner J (2014) 0.79
Alteration of the immunological synapse in lung cancer: a microenvironmental approach. Clin Exp Immunol (2008) 0.78
BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol (2011) 0.77
The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin Exp Immunol (2015) 0.77
T cell- but not tumor cell-produced TGF-β1 promotes the development of spontaneous mammary cancer. Oncotarget (2011) 0.77
Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun (2015) 0.76
Transforming Growth Factor-beta: A Therapeutic Target for Cancer. Hum Vaccin Immunother (2017) 0.75
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature (1997) 7.69
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev (1994) 5.65
Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature (1990) 4.90
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J (1997) 4.48
Smad6 inhibits signalling by the TGF-beta superfamily. Nature (1997) 4.34
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J (1994) 3.92
Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol (1986) 3.77
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology (1993) 2.86
SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev (1998) 2.76
The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Curr Biol (1997) 2.61
Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem (1994) 1.88
Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys (2000) 1.72
Transforming growth factor-beta: latent forms, binding proteins and receptors. Growth Factors (1993) 1.71
Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. FASEB J (1997) 1.65
Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother (1997) 1.64
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol (1994) 1.59
Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol (1995) 1.58
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Role of transforming growth factor beta in cancer. J Cell Physiol (2001) 1.46
Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem (1994) 1.44
Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature (1976) 1.41
Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem (1996) 1.41
Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin Chem (1997) 1.35
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A (1996) 1.30
Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A (1994) 1.29
Activation of latent transforming growth factor beta. Adv Pharmacol (1993) 1.26
Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol (1994) 1.19
Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem (1996) 1.16
High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev (1995) 1.16
Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4. J Biol Chem (2001) 1.15
Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res (2000) 1.15
Regulation of antibody production and class switching by TGF-beta. J Immunol (1995) 1.13
Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta (1992) 1.10
Transforming growth factor beta signaling through Smad1 in human breast cancer cells. Cancer Res (1998) 1.09
The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. J Biol Chem (1990) 1.08
Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther (1998) 1.07
TGF-beta receptors and signalling mechanisms. Miner Electrolyte Metab (1998) 1.06
Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann N Y Acad Sci (1993) 1.05
Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor-beta in murine microglial cell cultures. Clin Immunol Immunopathol (1995) 1.03
Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol (2001) 1.03
Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat (1997) 1.03
Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol (1996) 1.02
Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol (1999) 1.02
The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells. J Exp Med (1994) 1.01
The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer (1998) 1.01
Regulation of osteogenesis by fetuin. J Biol Chem (1999) 1.01
Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer (2001) 1.00
Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol (2001) 1.00
Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Crit Rev Oncog (1993) 1.00
In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res (1999) 0.99
Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res (1999) 0.99
TGF-beta: structure, function, and formation. Thromb Haemost (1993) 0.98
Distinct roles of the intracellular domains of transforming growth factor-beta type I and type II receptors in signal transduction. J Biol Chem (1994) 0.97
Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother (1995) 0.95
Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology (1994) 0.95
Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol (1993) 0.95
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer (1999) 0.94
Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg (1992) 0.93
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol (1997) 0.93
Transforming growth factor-beta signaling in epithelial cells. Pharmacol Ther (1997) 0.93
TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol (2000) 0.92
Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol (1998) 0.91
Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol (2000) 0.91
N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer (2001) 0.90
TGF-beta receptors: structure and function. Cell Mol Biol (Noisy-le-grand) (1994) 0.89
Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res (1995) 0.88
Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer (1994) 0.86
Transforming growth factor-beta in in vivo resistance. Cancer Chemother Pharmacol (1996) 0.86
Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel. Cell Calcium (1997) 0.86
Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol Med Chir (Tokyo) (1995) 0.86
Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol (1994) 0.86
Cytokine profile of cervical cancer cells. Gynecol Oncol (2001) 0.85
Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis (1998) 0.85
Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture. Dev Biol (1998) 0.84
Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res (1997) 0.84
Transforming growth factor beta and cancer. Cancer Treat Rev (1995) 0.84
Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer (1993) 0.84
Inhibitory effects of transforming growth factor-beta (TGF-beta) on certain functions of intraepithelial lymphocytes. Clin Exp Immunol (1999) 0.83
Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck (2001) 0.83
Transforming growth factor-beta: expression in normal and pathological conditions. Horm Res (1994) 0.83
TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. Prostate (2000) 0.83
Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine (1996) 0.82
Tranilast Kissei Pharmaceutical. IDrugs (1998) 0.82
Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer (1995) 0.81
Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer (1995) 0.81
Smads are the central component in transforming growth factor-beta signaling. Pharmacol Ther (1998) 0.81
Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice. Infect Immun (2000) 0.81
Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. J Immunother (1998) 0.80
Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis. Biotherapy (1994) 0.80
Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model. Cancer Biother (1994) 0.80